硫普罗宁对于乙型病毒性肝炎伴肺结核患者临床效果及对肝功能的改善分析

Analysis of the Clinical Effect of Tiopronin on Patients with Hepatitis B Accompanied by Tuberculosis and the Improvement of Liver Function

目的分析硫普罗宁(Tio)对于乙肝病毒性肝炎(乙肝)伴肺结核的疗效和对肝功能的改善效果。方法患者诊治时间介于2018年1月—2020年3月,共计乙肝伴肺结核患者94例。以随机法为准,A组计入例数48,予以化疗+保肝+Tio治疗。B组计入例数46,予以化疗+保肝治疗。对比临床疗效、肝功能指标变化、症状持续天数和不良反应率。结果A组统计病灶完全吸收率为93.75%,B组统计数据为73.91%,差异有统计学意义(χ^(2)=6.892,P=0.009);A组统计空洞完全闭合率为87.50%,B组统计数据69.57%,差异有统计学意义(χ^(2)=4.511,P=0.034);A组统计痰菌阴转率为91.67%,B组统计数据为73.91%,差异有统计学意义(χ^(2)=5.242,P=0.022)。治疗半年后,A组的丙氨酸氨基转移酶(ALT)值(96.32±10.25)U/L,B组值(106.25±12.32)U/L,差异有统计学意义(t=4.255,P<0.05);A组的总胆红素(TBIL)值(23.66±7.92)μmol/L,B组值(30.49±7.99)μmol/L,差异有统计学意义(t=4.162,P<0.05);A组的天门冬氨酸氨基转移酶(AST)值(84.22±16.34)U/L,B组值(94.77±16.82)U/L,差异有统计学意义(t=3.085,P=0.003)。A组的发热、盗汗以及咳嗽等症状持续天数均短于B组,差异有统计学意义(P<0.05)。A组统计不良反应率为6.25%,B组数据为8.70%,差异无统计学意义(χ^(2)=0.003,P=0.953)。结论为乙肝伴肺结核患者在基础性的化疗以及保肝治疗外,加用Tio可以保护肝功能,促进症状消退与病灶吸收,利于空洞完全闭合,且不会因加用药物增加不良反应。

Objective To analyze the effect of tiopronin(abbreviation Tio)on hepatitis B viral hepatitis(hepatitis B)with pulmonary tuberculosis and the improvement effect on liver function.Methods The diagnosis and treatment period of patients was between January 2018 and March 2020.There were 94 patients with hepatitis B and pulmonary tuberculosis.Based on the random method,group A was counted as 48 cases and received chemotherapy+liver protection+Tio treatment.Group B was counted as 46 cases and received chemotherapy+liver protection treatment.Compare the clinical efficacy,liver function index changes,symptom duration and adverse reaction rate.Results The statistical data of group A of total absurption rate of the lesions was 93.75%,the statistical data of group B was 73.91%,the difference was statistically significant(χ^(2)=6.892,P=0.009);the statistical data of group A inhole complete closure rate was 87.50%,and the statistical data of group B was 69.57%,the difference was statistically significant(χ^(2)=4.511,P=0.034);the statistical data of group A was 91.67%of negative conversion rate of sputum,and the statistical data of group B was 73.91%,the difference was statistically significant(χ^(2)=5.242,P=0.022).After half a year of treatment,the value of alanine aminotransferase(ALT)in group A was(96.32±10.25)U/L,and in group B was(106.25±12.32)U/L,the difference was statistically significant(t=4.255,P<0.05);the total bilirubin(TBIL)value of group A was(23.66±7.92)μmol/L,the value of group B was(30.49±7.99)μmol/L,the difference was statistically significant(t=4.162,P<0.05);group A of the value of aspartate aminotransferase(AST)was(84.22±16.34)U/L,and the value of group B was(94.77±16.82)U/L,the difference was statistically significant(t=3.085,P=0.003).The duration of symptoms such as fever,night sweats and cough in group A was shorter than that in group B,the difference was statistically significant(P<0.05).The statistical adverse reaction rate of group A was 6.25%,and the data of group B was 8.70%,the difference was not statistically significant(χ^(2)=0.003,P=0.953).Conclusion For patients with hepatitis B and pulmonary tuberculosis,in addition to basic chemotherapy and hepatoprotective treatment,the addition of Tio can protect liver function,promote symptom resolution and lesion absorption,and is conducive to complete closure of the cavity,and will not increase adverse reactions due to the addition of drugs.